Company intelligence / Profile preview

QGel

Lausanne, Vaud, Switzerland

Ownership: Private
Employees: ~16
Development stage: Other

Overview

QGel develops fully synthetic, tunable hydrogels that mimic the extracellular matrix (ECM) for growing 3D organoids and tumouroids in vitro, primarily for drug discovery and personalized cancer research. Their technology enables scalable, physiologically relevant models that improve the predictive value of preclinical testing and are increasingly used in pharmaceutical partnerships and cancer diagnostics.

Therapeutic areas: OncologyOther
Modalities: Synthetic hydrogel matrix systems3D cell culture systems
Industry: Non-Drug Biotech

Partnerships

Partnerships with pharmaceutical companies (unspecified names)

Beyond the preview

Go deeper on QGel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QGel.

Explore the full profile